LCM
VIR icon

Laurion Capital Management’s Vir Biotechnology VIR Stock Holding History

Laurion Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,749
Closed -$451K – 721
2021
Q4 		$451K Hold
10,749
– – ﹤0.01% 432
2021
Q3 		$468K Hold
10,749
– – ﹤0.01% 577
2021
Q2 		$508K Buy
+10,749
New +$489K ﹤0.01% 510

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return

Laurion Capital Management's VIR Position: Q1 2022 in Review

Laurion Capital Management sold out of Vir Biotechnology (VIR) in Q1 2022, closing a stake of 10,749 shares — an estimated $451K sold.

Laurion Capital Management first reported a position in VIR in Q2 2021 and held it in 3 quarters. The position peaked at $508K in Q2 2021. 204 funds tracked by Wall St. Rank hold VIR as of Q1 2022.

  • Laurion Capital Management reported no remaining Vir Biotechnology position as of Q1 2022 after selling out during the quarter.
  • Laurion Capital Management sold 10,749 Vir Biotechnology shares in Q1 2022, an estimated $451K.
  • Laurion Capital Management first reported a position in Vir Biotechnology in Q2 2021 and held it in 3 quarters.
  • Laurion Capital Management's Vir Biotechnology position peaked at $508K in Q2 2021.
  • 204 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2022.

Based on Laurion Capital Management's 13F filing for Q1 2022, filed 16 May 2022.